Anhydroicaritin improves diet-induced obesity and hyperlipidemia and alleviates insulin resistance by suppressing...

Area of Science:

• Biochemistry
• Metabolic Disease Research
• Drug Discovery

Background:

• Sterol Regulatory Element-Binding Proteins (SREBPs) are key regulators of lipid metabolism and implicated in metabolic diseases.
• Targeting SREBPs with small molecules is a promising therapeutic strategy, yet no drugs are currently available.
• There is a critical need for specific small-molecule inhibitors of SREBPs.

Purpose of the Study:

• To identify novel small molecules that inhibit SREBPs.
• To investigate the mechanism of action of identified inhibitors.
• To evaluate the therapeutic potential of these inhibitors in preclinical models of metabolic disease.

Main Methods:

• High-throughput screening using hepatocytes to identify SREBP inhibitors.
• In vitro validation using HepG2, HL-7702, and primary human hepatocytes.
• Mechanistic studies involving the LKB1/AMPK/mTOR pathway and SCAP/SREBPs complex.
• In vivo studies using diet-induced obese mice.

Main Results:

• Anhydroicaritin (AHI) was identified as a novel SREBP inhibitor.
• AHI blocks SCAP/SREBPs complex binding to Sec23α/24D by regulating the LKB1/AMPK/mTOR pathway.
• AHI reduces hepatic de novo lipogenesis, ameliorates obesity, insulin resistance, hepatic steatosis, and hyperlipemia in mice.

Conclusions:

• AHI suppresses SREBP maturation via the LKB1/AMPK/mTOR pathway, improving diet-induced obesity and insulin resistance.
• AHI demonstrates potential as a leading compound for the pharmacological control of metabolic diseases.
• Targeting SREBP maturation presents a viable strategy for treating metabolic disorders.